Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin alfa for presurgical autologous blood donation
NCT00270075Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Jan 1990
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, randomised, double-blind trial of epoetin alfa (4 arms), sponsored by Johnson & Johnson. Primary endpoints: Number of self-donated units of blood collected within 2 weeks and Change in hemoglobin level from before the start of the study to the end of the study at 2 weeks. Started Jan 1990; status: completed.
02
Drugs
epoetin alfa
Beyond the preview
Go deeper on NCT00270075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00270075.